Production (Stage)
Celldex Therapeutics, Inc.
CLDX
$20.34
-$0.92-4.33%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -14.24% | -11.80% | -17.52% | -9.25% | 24.24% |
| Total Depreciation and Amortization | 5.86% | 4.20% | -1.38% | 2.84% | 2.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.84% | 21.36% | 82.45% | -25.58% | -22.57% |
| Change in Net Operating Assets | -215.18% | 138.23% | -784.63% | 122.54% | -350.99% |
| Cash from Operations | -67.42% | 41.31% | -88.69% | 27.83% | -24.91% |
| Capital Expenditure | 64.95% | -38.72% | -98.91% | 20.35% | 48.35% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 74.23% | -48.65% | 203.99% | 85.25% | -84.68% |
| Cash from Investing | 78.61% | -49.65% | 202.22% | 85.18% | -84.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -47.67% | -68.85% | -66.62% | -99.15% | 100.63% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -47.67% | -68.85% | -66.62% | -99.15% | 100.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -39.50% | -26.86% | 91.24% | -190.13% | 486.72% |